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1. INTRODUCTION {#cas14177-sec-0001}
===============

Non‐small cell lung cancer (NSCLC) is the most common type of cancer and a leading cause of cancer‐associated mortality worldwide.[1](#cas14177-bib-0001){ref-type="ref"} Detection of driver genes in patients with NSCLC has become standard for clinical decision‐making. Rearrangement of the anaplastic lymphoma kinase (*ALK*) gene has been identified as a specific molecular subtype in NSCLC and patients with this rearrangement respond to *ALK* tyrosine kinase inhibitors (TKI).[2](#cas14177-bib-0002){ref-type="ref"}, [3](#cas14177-bib-0003){ref-type="ref"}, [4](#cas14177-bib-0004){ref-type="ref"} Although ALK‐TKI can dramatically improve the clinical efficacy, responses have been shown to widely vary between patients.[5](#cas14177-bib-0005){ref-type="ref"} Therefore, it is critical to determine the potential mechanisms associated with the heterogeneous outcomes.

In addition to *ALK*, several other oncogenic driver genes, including epidermal growth factor receptor [(]{.smallcaps} *EGFR*), *ROS1*,*BRAF*,*MET*,*RET* and *ERBB2*, have been defined as important targets in NSCLC.[6](#cas14177-bib-0006){ref-type="ref"} Traditional detection methods of *ALK* rearrangements, including FISH and immunohistochemistry (IHC), are limited by certain technical limitations, including signal instability and scoring difficulties.[7](#cas14177-bib-0007){ref-type="ref"}, [8](#cas14177-bib-0008){ref-type="ref"} Additionally, these detection methods are unable to interrogate different driver gene mutations at the same time. Next‐generation sequencing (NGS) has become an alternative method for determining *ALK* fusions in NSCLC with high sensitivity and specificity,[9](#cas14177-bib-0009){ref-type="ref"} which can also simultaneously detect multiple gene alterations and complete a comprehensive analysis of genomic alterations, including single nucleotide variations, insertions, deletions, copy number variations and chromosomal rearrangements. At present, detection of genomic alterations predominantly relies on the analysis of cancer tissues obtained by surgical excision or biopsy. However, tumor tissues are not always available from all patients and a tissue biopsy of a single site may not fully reflect the tumor genomic landscape due to tumor genetic heterogeneity, which limits the utility of tissue‐based sequencing.[10](#cas14177-bib-0010){ref-type="ref"}, [11](#cas14177-bib-0011){ref-type="ref"} Circulating tumor DNA (ctDNA), released into the plasma from apoptotic and necrotic tumor cells originating from primary tumors and metastatic lesions, comprises tumor‐specific sequence alterations and may be an alternative to tissue sample biopsies.[12](#cas14177-bib-0012){ref-type="ref"}, [13](#cas14177-bib-0013){ref-type="ref"} A number of studies have indicated that a ctDNA assay could be used for patients without acquirable tissue samples to screen for genetic variations and thus guide treatment decisions for patients with NSCLC.[14](#cas14177-bib-0014){ref-type="ref"}, [15](#cas14177-bib-0015){ref-type="ref"}, [16](#cas14177-bib-0016){ref-type="ref"} Plasma ctDNA is not suitable for the detection of *ALK* rearrangements by IHC or FISH methods as it is highly fragmented DNA of approximately 150 bp and cannot provide protein information.[17](#cas14177-bib-0017){ref-type="ref"}, [18](#cas14177-bib-0018){ref-type="ref"} In contrast, ctDNA‐based NGS assays serve a crucial role in simultaneously identifying *ALK* arrangements and other driver gene alterations in patients with NSCLC whose tumor samples are insufficient or unobtainable.

Fusion partners of the *ALK* gene are variable, including *EML4*,*KIF5B*,*HIP1*,*TFG* and more.[19](#cas14177-bib-0019){ref-type="ref"}, [20](#cas14177-bib-0020){ref-type="ref"}, [21](#cas14177-bib-0021){ref-type="ref"} *EML4* is the most common partner in *ALK* translocation‐positive patients with NSCLC, but breakpoints within the *EML4* gene often occur at different sites. Among the *EML4‐ALK* variants identified in previous studies, variant V1 \[exon 13 of *EML4* fuses to exon 20 of *ALK* (E13;A20)\] and variant V3 \[exon 6 of *EML4* fuses to exon 20 of *ALK* (E6;A20)\] have been shown to be the most predominant.[22](#cas14177-bib-0022){ref-type="ref"}, [23](#cas14177-bib-0023){ref-type="ref"}, [24](#cas14177-bib-0024){ref-type="ref"} Variant V3 has recently been identified as a high‐risk factor in *ALK* translocation‐positive lung adenocarcinoma, which is correlated with metastasis and short overall survival (OS).[25](#cas14177-bib-0025){ref-type="ref"}, [26](#cas14177-bib-0026){ref-type="ref"}, [27](#cas14177-bib-0027){ref-type="ref"}

Although a few studies have evaluated the frequency of *ALK* rearrangements in Chinese patients with NSCLC,[28](#cas14177-bib-0028){ref-type="ref"}, [29](#cas14177-bib-0029){ref-type="ref"} the genetic profile of *ALK* fusions has not been particularly well studied. Using NGS‐based tissue and ctDNA assays with a large NSCLC cohort, the current study investigated the genomic landscape and characterized the heterogeneity of *ALK* fusions. In addition, the clinical and molecular characteristics of *ALK*‐positive patients were further analyzed, which may provide comprehensive knowledge of the complexity of this population.

2. MATERIALS AND METHODS {#cas14177-sec-0002}
========================

2.1. Sample collection {#cas14177-sec-0003}
----------------------

The present study enrolled 1688 patients with NSCLC who were treated at multiple hospitals across China, including Affiliated Sir Run Run Shaw Hospital of Zhejiang University (Hangzhou), Zhejiang Cancer Hospital (Hangzhou), Quzhou People\'s Hospital (Quzhou), Lishui Municipal Central Hospital (Lishui) and First Affiliated Hospital of Wenzhou Medical University (Wenzhou) between September 2017 and February 2019. The specimens obtained included 885 plasma and 803 tissue samples. Inclusion criteria for the patients were as follows: (i) patients were diagnosed with NSCLC; and (ii) at least 150 ng and 15 ng DNA from each tissue and ctDNA sample, respectively, were successfully extracted. Patients who had other malignant tumors and serious mental illness were excluded. All experiments were carried out in accordance with the relevant guidelines and regulations of the ethical committees of the participating hospitals. Written informed consent was obtained from all participants.

2.2. DNA extraction and library preparation {#cas14177-sec-0004}
-------------------------------------------

ctDNA was isolated from at least 2 mL plasma with a QIAamp Circulating Nucleic Acid kit (Qiagen GmbH), according to the manufacturer\'s protocol. Tissue DNA was extracted using the QIAamp Genomic DNA kit (Qiagen GmbH). Quality and quantification of the DNA were assessed using the Agilent 2100 BioAnalyzer (Agilent Technologies, Inc.) and Qubit ds DNA HS assay kit (Thermo Fisher Scientific, Inc.). Sequencing libraries were constructed according to the Illumina standard library construction instructions (Illumina, Inc.).

2.3. Next‐generation sequencing {#cas14177-sec-0005}
-------------------------------

The various libraries were hybridized with a nine‐gene panel, which was enriched for the coding regions and selected introns of genes with known relevance to NSCLC. The target‐enriched libraries were pooled and sequenced on an Illumina HiSeq2500 NGS platform (Illumina, Inc.). Sequencing depth was \>10 000×. Genomic data were then processed by a relevant bioinformatics platform. Multiple types of genomic alterations, including single‐nucleotide variants, small insertions or deletions, copy number variants and rearrangements of *ALK*,*RET* and *ROS1* were identified.

2.4. Statistical analysis {#cas14177-sec-0006}
-------------------------

SPSS 21.0 statistical software (IBM Corp.) was used to analyze the data. Associations between *ALK* rearrangements and clinical characteristics were analyzed using Fisher\'s exact test or chi‐squared test. Differences in continuous variables were assessed with Student\'s *t*‐test. A two‐sided *P *\<* *.05 was considered to indicate a statistically significant difference.

3. RESULTS {#cas14177-sec-0007}
==========

3.1. Identification and incidence rate of *ALK* rearrangements in NSCLC {#cas14177-sec-0008}
-----------------------------------------------------------------------

In the present study, a total of 1688 patients diagnosed with NSCLC were enrolled. NGS was carried out for 885 plasma ctDNA and 803 tissue samples. In total, 70 cases with *ALK* rearrangements were identified, with an overall incidence rate of 4.1%. According to the sample category, the frequencies of *ALK* fusions detected in tissue and plasma samples were 5.1% and 3.3%, respectively. Although the frequency of *ALK* fusions detected by ctDNA profiling was lower compared with that detected by tissue sequencing, no statistically significant differences were observed (*P *=* *.067) (Table [1](#cas14177-tbl-0001){ref-type="table"}).

###### 

Frequencies of *ALK* rearrangements among 1688 patients with NSCLC

  Histological type   Total   *ALK* rearrangements status               
  ------------------- ------- ----------------------------- ----- ----- ------
  Tissue              803     41                            762   5.1   .067
  ctDNA               885     29                            856   3.3   

ALK, anaplastic lymphoma kinase; ctDNA, circulating tumor DNA; Freq, frequency of *ALK* rearrangements; NSCLC, non‐small cell lung cancer.
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3.2. Molecular and clinical characteristics of patients with *ALK* rearrangements {#cas14177-sec-0009}
---------------------------------------------------------------------------------

Among all patients, median age at diagnosis was 62 years (range: 24‐89 years) and 57.0% of the patients were male. Patients with *ALK* fusions were significantly younger than those without *ALK* fusions (median age: 53 vs 62 years, *P *\<* *.001). Previous studies have reported age cutoff points of 45 and 70 years to determine a patient as young or elderly, respectively.[30](#cas14177-bib-0030){ref-type="ref"}, [31](#cas14177-bib-0031){ref-type="ref"} In the present study, the frequencies of *ALK* fusions between young (\<45 years), middle‐aged (between 45 and 70 years) and elderly (\>70 years) patients were compared. As presented in Figure [1](#cas14177-fig-0001){ref-type="fig"}, the prevalence of *ALK* fusions in young patients was significantly higher compared with the other two groups (*P *\<* *.001). Additionally, middle‐aged patients showed higher frequencies of *ALK* fusions compared with elderly patients (3.8% vs 2.2%), whereas no statistically significant difference was observed (*P *=* *.160). Further analysis showed that *ALK* rearrangements were significantly associated with females (*P *=* *.019). Patients without *EGFR* or *KRAS* mutations more frequently presented with *ALK* rearrangements compared with patients with *EGFR* or *KRAS* mutations (7.0% vs 1.5%, *P *\<* *.001; 4.8% vs 0.4%, *P *=* *.001, respectively). Furthermore, a potentially statistical difference was identified between the frequencies of *ALK* rearrangements in patients with and without *ERBB2* mutations (1.3% vs 4.4%, respectively, *P *=* *.058) (Table [2](#cas14177-tbl-0002){ref-type="table"}).

![Prevalence of anaplastic lymphoma kinase (*ALK*) rearrangements in young (\<45 y), middle‐aged (between 45 and 70 y) and elderly patients (\>70 y) with non‐small cell lung cancer. Statistical significance was defined as *P* \< .05](CAS-110-3382-g001){#cas14177-fig-0001}

###### 

Association analysis between *ALK* rearrangements and clinical or molecular characteristics

  Characteristic           Total        *ALK* rearrangements status   Negative     Freq (%)   *P* value
  ------------------------ ------------ ----------------------------- ------------ ---------- -----------
  Age, y, median (range)   62 (24‐89)   53 (32‐83)                    62 (24‐89)              \<.001
  Gender                                                                                      
  Male                     963          31                            932          3.2        .039
  Female                   703          39                            664          5.5        
  Unknown                  22           0                             22           0          
  *EGFR*                                                                                      
  Wild type                813          58                            755          7.1        \<.001
  Mutations                875          12                            863          1.4        
  *KRAS*                                                                                      
  Wild type                1429         69                            1360         4.8        \<.001
  Mutations                259          1                             258          0.4        
  *ERBB2*                                                                                     
  Wild type                1531         68                            1463         4.4        .058
  Mutations                157          2                             155          1.3        

ALK, anaplastic lymphoma kinase; Freq, frequency of *ALK* rearrangements.
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3.3. Genomic heterogeneity of *ALK* rearrangements {#cas14177-sec-0010}
--------------------------------------------------

For *ALK* translocation‐positive patients, the frequency of the *EML4* gene as the predominant partner of *ALK* was 84.3% (Figure [2](#cas14177-fig-0002){ref-type="fig"}A). Previously reported partners of *ALK* identified in the present study included *KIF5B*,*HIP1* and *TFG*, and novel *ALK* fusion partners included *TRIM66*,*SWAP70*,*WNK3*,*ERC1*,*TCF12* and *FBN1* (Table [3](#cas14177-tbl-0003){ref-type="table"}). Among the *EML4‐ALK* fusion variants, frequencies of variant V1, variant V2 and variant V3 were 38.9%, 15.3% and 30.5%, respectively (Figure [2](#cas14177-fig-0002){ref-type="fig"}B). An increasing number of studies have reported that patients with different *EML4‐ALK* variants show heterogeneous clinical outcomes to ALK‐TKI for NSCLC.[25](#cas14177-bib-0025){ref-type="ref"}, [26](#cas14177-bib-0026){ref-type="ref"}, [27](#cas14177-bib-0027){ref-type="ref"} Therefore, we hypothesized that molecular or clinical characteristics associated with different variants might show some difference. In the present study, the age of patients with variant V1 was significantly younger compared with that of patients with variant V3. Additionally, the frequency of *TP53* concurrent with variant V3 was markedly higher compared with that of *TP53* concurrent with variant V1 (Figure [2](#cas14177-fig-0002){ref-type="fig"}C,D). Further analysis indicated that prevalence of breakpoint locations for *EML4‐ALK* fusions found in ctDNA was strongly correlated with that found in tumor tissues (*R* ^2^ = .91, *P *=* *.045) (Figure [3](#cas14177-fig-0003){ref-type="fig"}).

![Genomic heterogeneity of anaplastic lymphoma kinase (*ALK*) rearrangements and characteristics of patients with different *EML4‐ALK* variants. A, Frequency of *EML4* and non‐*EML4* partners of *ALK* fusions. B, Frequency of different *EML4‐ALK* fusion variants. C, Age difference between *EML4‐ALK* fusion variant V1 and variant V3 patients. D, Distribution of *TP53* mutations between *EML4‐ALK* fusion variant V1 and variant V3 patients. WT, wild type](CAS-110-3382-g002){#cas14177-fig-0002}

###### 

Distribution of non‐*EML4* partners of *ALK* fusions in the present study

  Non‐*EML4* fusion partners   No. of patients
  ---------------------------- -----------------
  *KIF5B*                      2
  *HIP1*                       2
  *TFG*                        1
  *TRIM66*                     1
  *SWAP70*                     1
  *WNK3*                       1
  *ERC1*                       1
  *TCF12*                      1
  *FBN1*                       1

ALK, anaplastic lymphoma kinase.

John Wiley & Sons, Ltd

![Correlation analysis between frequencies of different variants of *EML4‐ALK* fusions in ctDNA and tissue specimens. Variant V1, exon 13 of *EML4* fuses to exon 20 of *ALK*; variant V2, exon 20 of *EML4* fuses to exon 20 of *ALK*; variant V3, exon 6 of *EML4* fuses to exon 20 of *ALK*. *ALK*, anaplastic lymphoma kinase; ctDNA, circulating tumor DNA](CAS-110-3382-g003){#cas14177-fig-0003}

3.4. Case with longitudinal ctDNA *ALK* analysis {#cas14177-sec-0011}
------------------------------------------------

During the present study, a 52‐year‐old male patient was diagnosed with brain metastases of lung adenocarcinoma in June 2016 and was treated with six cycles of chemotherapy including cisplatin and gemcitabine. After 8 months, the patient presented with progressive disease (PD) and analysis of the tissue specimen by Sanger sequencing and FISH showed that the patient carried *EML4‐ALK* fusion but no *EGFR* mutation; therefore, the patient received crizotinib treatment. However, disease progression was observed after 7 months and the patient showed a poor performance status. The patient\'s plasma ctDNA sample was then evaluated by NGS to investigate the potential resistance mechanisms and guide the subsequent therapy. *EML4‐ALK* fusion, *ALK G1202R*, and *TP53 A74 fs* mutations were identified, and the mutant allele frequencies of these were 2.68%, 0.85%, and 3.01%, respectively. Based on the current National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC (version 8.2017), the patient was given brigatinib after crizotinib treatment. However, the patient experienced rapid disease progression within 3 months, at which time the plasma ctDNA sample was reassessed. *ALK* rearrangement, *ALK G1202R*, and *TP53 A74 fs* mutations were identified again; however, no novel mutations were detected. These data showed that the abundance of *EML‐ALK* fusions and *TP53 A74 fs* mutations decreased dramatically (to 0.81% and 1.06%, respectively), whereas the abundance of *ALK G1202R* mutations increased and reached a relatively high level (to 1.94%) (Figure [4](#cas14177-fig-0004){ref-type="fig"}). Based on the NGS result, further analysis showed that the variant type of *EML4‐ALK* fusion in this case was variant V3, which was consistent with the finding that variant V3 of *EML4‐ALK* fusion tended to coexist with *TP53* mutation.

![Longitudinal analysis of plasma ctDNA *ALK* alterations from a patient. A, Timeline indicates different treatments. B, Map of clonal evolution. Two plasma ctDNA samples analyzed by next‐generation sequencing (NGS) were collected during different treatments. Different colors represent different gene mutations. *ALK*, anaplastic lymphoma kinase; ARMS, amplification refractory mutation system; ctDNA, circulating tumor DNA; fs, frameshift mutation](CAS-110-3382-g004){#cas14177-fig-0004}

3.5. Analysis of concurrent *ALK* rearrangements and other driver gene mutations {#cas14177-sec-0012}
--------------------------------------------------------------------------------

Although previous studies have reported that *ALK* rearrangements are mutually exclusive with other driver gene mutations in NSCLC, a number of studies have identified that *ALK* fusions coexist with other genomic alterations, and such co‐alterations may affect the therapeutic outcome of patients.[32](#cas14177-bib-0032){ref-type="ref"}, [33](#cas14177-bib-0033){ref-type="ref"}, [34](#cas14177-bib-0034){ref-type="ref"} As NGS can simultaneously detect multiple gene alterations, the concurrent pattern of *ALK* fusions with other driver gene alterations, including *EGFR*,*ROS1*,*BRAF*,*MET*,*ERBB2*,*RET* and *KRAS*, were analyzed in the present study. Among 70 *ALK*‐positive cases, the coexistence of *ALK* fusions and *EGFR* mutations was detected in 12 cases (17.1%) (Figure [5](#cas14177-fig-0005){ref-type="fig"}). According to *EGFR* mutant categories, *ALK* fusions primarily coexisted with *EGFR* general mutant types, including *EGFR* exon 19 deletion and *EGFR* exon 21 *L858R* mutation ([Figure S1](#cas14177-sup-0001){ref-type="supplementary-material"}). The frequency of co‐alteration between *ALK* rearrangements and *EGFR* exon 19 deletion tended to be higher compared with that between *ALK* rearrangements and *EGFR* exon 21 *L858R* mutation, but no significant statistical difference was identified (1.46% vs 0.67%, *P *=* *.341). According to the types of *ALK* fusion partner, non*‐EML4‐ALK* fusions tended to coexist with *EGFR* alterations (*P *=* *.065) ([Figure S2](#cas14177-sup-0001){ref-type="supplementary-material"}). In addition, concurrent *MET* amplification, and *ERBB2* and *KRAS* mutations were also observed in *ALK* rearrangement‐positive patients (Figure [5](#cas14177-fig-0005){ref-type="fig"}). No *BRAF*,*ROS1* and *RET*‐associated variations concurrently presented with *ALK* fusions.

![Genetic profiles in patients with *ALK*‐rearranged non‐small cell lung cancer. Samples of 70 patients harboring *ALK* fusions were analyzed by targeted next‐generation sequencing assays. *ALK*, anaplastic lymphoma kinase; *EGFR*, epidermal growth factor receptor](CAS-110-3382-g005){#cas14177-fig-0005}

4. DISCUSSION {#cas14177-sec-0013}
=============

The present study provided an overview of the prevalence and features of genomic heterogeneity of *ALK* fusions in a large cohort of Chinese patients with NSCLC. Previous studies have reported that the frequency of *ALK* fusion is \~2%‐7% in NSCLC.[35](#cas14177-bib-0035){ref-type="ref"}, [36](#cas14177-bib-0036){ref-type="ref"}, [37](#cas14177-bib-0037){ref-type="ref"} The incidence rate of *ALK* rearrangements in the current study was 4.1%, which is comparable with the previously published data. Frequencies of *ALK* fusions detected in tissue and plasma samples were 5.1% and 3.3%, respectively. To the best of our knowledge, the present study is the first to simultaneously evaluate the prevalence of *ALK* rearrangements in a large number of tissue and plasma ctDNA samples, and comprehensively analyze the concurrent status of *ALK* rearrangements and other driver gene mutations in NSCLC. Although the frequency of *ALK* rearrangement in ctDNA was lower compared with that in tissue samples, the present data indicated that detection of *ALK* translocations by ctDNA‐based NGS was required to guide treatment decisions in patients with NSCLC with inadequate or unacquirable tissue samples. Moreover, breakpoint patterns of *EML4‐ALK* fusions between ctDNA and tissue samples were also compared, and frequencies of different *EML4‐ALK* variants in ctDNA samples showed a strong similarity with those observed in tumor tissues, further supporting the feasibility and use of plasma ctDNA for detection of *ALK* fusions among patients with NSCLC. Incidence rates of *ALK* fusions among young, middle‐aged, and elderly patients showed significant differences, which indicates that in NSCLC the genomic landscape among different age categories is diverse. According to previous studies, *ALK* fusions either do not differ among different genders or generally occur more frequently in females,[38](#cas14177-bib-0038){ref-type="ref"} whereas Kang et al[39](#cas14177-bib-0039){ref-type="ref"} reported that *ALK*‐positive patients were more commonly male. The present results also showed a markedly higher prevalence of *ALK* fusions in female patients.

All samples were profiled by targeted sequencing with a panel of nine of the most common driver genes in NSCLC, including *EGFR*,*ALK*,*ROS1*,*BRAF*,*MET*,*RET*,*ERBB2*,*KRAS* and *TP53*. Among the *ALK*‐positive cases, 17.1% of patients were identified to show concurrent *EGFR* mutations and *ALK* fusions. Although a number of studies have reported that *ALK* rearrangements are not frequently concomitant with *EGFR* mutations,[40](#cas14177-bib-0040){ref-type="ref"}, [41](#cas14177-bib-0041){ref-type="ref"} the current results showed that such co‐alterations accounted for a relatively high proportion of *ALK* rearrangement‐positive patients with NSCLC. EGFR‐TKI and ALK‐TKI have been approved for *EGFR* mutation‐positive and *ALK* translocation‐positive advanced NSCLC, respectively.[42](#cas14177-bib-0042){ref-type="ref"} However, the clinical activity of EGFR‐TKI and ALK‐TKI among patients with such co‐alterations remains largely unknown and how to use these TKI remains controversial. Limited studies found that the response rate to both TKI in this population appears to be slightly lower compared with that in *EGFR* mutation‐positive or *ALK* rearrangement‐positive patients.[43](#cas14177-bib-0043){ref-type="ref"} Additionally, several studies have reported that different orders of treatment lines of EGFR‐TKI and ALK‐TKI affect the therapeutic outcomes of this subgroup of patients.[32](#cas14177-bib-0032){ref-type="ref"}, [33](#cas14177-bib-0033){ref-type="ref"}, [34](#cas14177-bib-0034){ref-type="ref"} Moreover, numerous studies reported that *EGFR* mutation and *ALK* rearrangements may coexist in the same tumor cells[44](#cas14177-bib-0044){ref-type="ref"} or may occur in different lesions of the tumor,[45](#cas14177-bib-0045){ref-type="ref"} which may have an effect on the treatment strategies.[46](#cas14177-bib-0046){ref-type="ref"} As ctDNA was released from tumor lesions of the whole body, the result of *ALK/EGFR* co‐alteration from ctDNA should be further verified by tissue samples from different tumor foci in patients with multifocal NSCLC if possible, in order to clarify the intratumoral or intertumoral coexistence of such co‐alteration and guide the subsequent therapy. Therefore, the treatment strategies for patients with NSCLC harboring such co‐alterations deserve more attention. NGS can simultaneously detect multiple genomic alterations with tissue or plasma ctDNA samples; therefore, the present study comprehensively and simultaneously assessed *EGFR* mutations and *ALK* fusions, with the aim of establishing optimal treatment decisions for *EGFR* and *ALK* mutation‐positive patients with NSCLC. In addition to *EGFR* mutations, this study also showed that *ALK* rearrangements were concurrent with *KRAS*,*ERBB2*, and *MET* mutations, which may have important consequences regarding treatment. Therefore, the selection of optimal targeted therapy is crucial for this population.

FISH is approved as the gold standard for detecting *ALK* fusions and IHC is an effective routine examination approach; however, neither of these methods can distinguish between different *ALK* translocation variants. NGS has increasingly been applied for the analysis of gene fusions in clinical cancer samples, particularly for identifying novel partner genes of *ALK* fusions. Although numerous studies have reported that the *ALK* gene fuses with a number of genes in NSCLC,[19](#cas14177-bib-0019){ref-type="ref"}, [20](#cas14177-bib-0020){ref-type="ref"}, [21](#cas14177-bib-0021){ref-type="ref"} new fusion partner genes are increasingly being discovered. In the present study, novel *ALK* fusion partner genes, including *TRIM66*,*SWAP70*,*WNK3*,*ERC1*,*TCF12* and *FBN1* were identified, which encompass specific domains such as coiled‐coil, basic helix‐loop‐helix (bHLH) and proline/glycine‐rich regions mediating the dimerization of these genes.[47](#cas14177-bib-0047){ref-type="ref"}, [48](#cas14177-bib-0048){ref-type="ref"}, [49](#cas14177-bib-0049){ref-type="ref"}, [50](#cas14177-bib-0050){ref-type="ref"}, [51](#cas14177-bib-0051){ref-type="ref"}, [52](#cas14177-bib-0052){ref-type="ref"} This dimerization might result in activation of the tyrosine kinase function of *ALK* and thereby confers marked tumorigenic activity. Additionally, the result also indicated that a technical limitation of FISH and IHC may be the identification of novel *ALK* fusion partners, which affects the personal therapy of patients. It is well known that *EML4* is the most frequent and studied *ALK* fusion partner gene. Among the *EML4*‐*ALK* fusion variants evaluated in the current study, variant V1 (37.2%) and variant V3 (32.2%) were the most prevalent, which was similar to previous reports.[24](#cas14177-bib-0024){ref-type="ref"} An increasing number of studies have indicated that different *EML4*‐*ALK* variants have an impact on the prognosis of *EML4*‐*ALK*‐positive NSCLC patients. According to these publications, variant V3 tends to be a higher risk feature associated with poor prognosis compared with variant V1.[25](#cas14177-bib-0025){ref-type="ref"}, [26](#cas14177-bib-0026){ref-type="ref"}, [27](#cas14177-bib-0027){ref-type="ref"} The present study identified that the age of patients with variant V3 was significantly older compared with that of patients with variant V1. According to previous studies, young patients with lung cancer show improved survival.[53](#cas14177-bib-0053){ref-type="ref"}, [54](#cas14177-bib-0054){ref-type="ref"} The present data provide a novel insight into the differences in prognosis between *EML4*‐*ALK* variant V1 and variant V3 patients. A number of studies have demonstrated that *TP53* mutations predict a poor outcome following systemic therapy for *ALK* fusion NSCLC, and co‐alterations between *EML4*‐*ALK* variant V3 and *TP53* mutations define a patient subset with worse prognosis.[55](#cas14177-bib-0055){ref-type="ref"}, [56](#cas14177-bib-0056){ref-type="ref"}, [57](#cas14177-bib-0057){ref-type="ref"} The present study demonstrated that the frequency of concurrent *TP53* mutations and *EML4*‐*ALK* variant V3 was markedly higher compared with that of concurrent *TP53* mutations and *EML4*‐*ALK* variant V1, which indicates that *TP53* mutation may be one of the critical reasons for the differences in prognosis between patients with *EML4*‐*ALK* variant V1 and variant V3 NSCLC.

Among the *ALK* translocation‐positive patients, there was a case with longitudinal plasma ctDNA samples. An *EML4*‐*ALK* fusion was identified at the time of initial diagnosis by FISH with a tissue specimen and the patient was then given crizotinib. However, disease progression was observed after 7 months with crizotinib treatment. Further molecular characterization with a plasma ctDNA sample showed *EML4*‐*ALK* fusion, and *ALK* *G1202R* and *TP53* *A74 fs* mutations. According to the current guidelines for NSCLC, the patient was subsequently given brigatinib; however, the patient experienced rapid disease progression within 3 months. Further investigation using ctDNA samples based on NGS assays showed that the abundance of *EML*‐*ALK* fusions and *TP53* *A74 fs* mutations decreased markedly, whereas the abundance of *ALK* *G1202R* mutations increased to a relatively high level, which indicates that the *ALK* *G1202R* mutation may be associated with brigatinib resistance. Although limited studies have previously reported that ctDNA could be used for *ALK* fusion detection,[58](#cas14177-bib-0058){ref-type="ref"}, [59](#cas14177-bib-0059){ref-type="ref"} the present results further demonstrated the clinical utility of ctDNA for the detection of *ALK* fusions and the investigation of molecular mechanisms of *ALK* inhibitor resistance in NSCLC. According to the current guidelines for NSCLC, second‐generation ALK‐TKI, including brigatinib and ceritinib, are recommended for *ALK*‐positive patients following failure of crizotinib therapy. However, the patient in the present study experienced rapid progression following brigatinib treatment. At the time of identification of *ALK* *G1202R*, several studies reported that the *ALK* *G1202R* mutation is associated with first‐generation and second‐generation ALK‐TKI resistance, and third‐generation ALK‐TKI, including lorlatinib, potentially overcome this resistance.[60](#cas14177-bib-0060){ref-type="ref"}, [61](#cas14177-bib-0061){ref-type="ref"} The unsatisfactory clinical response of brigatinib treatment in the current case also suggests that there should be more focus on individualized medicine in cancer treatment, rather than a total dependence on relevant guidelines for the guidance of treatment decisions.

In conclusion, the present study evaluated a large prospective cohort to investigate the prevalence of *ALK* fusions in Chinese patients with NSCLC using targeted sequencing technology with tissue and plasma samples. The results showed that plasma ctDNA samples can serve crucial roles in detecting *ALK* fusions or resistant mutations among patients with inadequate or unacquirable tissue samples for molecular testing, which greatly contributes to the guidance of treatment decisions for these patients. Identification of novel *ALK* fusion partners, coexistence between *ALK* fusions and variants of other oncogenic drivers, and the characterization of *EML4*‐*ALK*‐postive patients support the critical use of molecular profiling by NGS in NSCLC.
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